Stock Market & Financial Investment News

News Breaks December 18, 2012 09:40 EDT VNDA Vanda Pharmaceuticals held a conference call Conference call to discuss positive Phase III results for Tasimelteon for the treatment of a non-24 hour disorder was held on December 18 at 9 am and has a replay available from 11 am on December 18 through December 25. Webcast Link News For VNDA From The Last 14 Days Check below for free stories on VNDA the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 17, 2013 19:06 EDT VNDA Vanda says Phase III study data shows cortisol rhythm restoration Subscribe for More Information June 11, 2013 11:24 EDT VNDA High option volume stocks: ABC VNDA TTWO ARMH AMTD Subscribe for More Information June 6, 2013 05:21 EDT VNDA Vanda Pharmaceuticals presents data from Tasimelteon Phase III study Subscribe for More Information June 4, 2013 11:48 EDT VNDA High option volume stocks: MTL DPM VNDA SHPG BMRN 08:05 EDT VNDA Vanda Pharmaceuticals price target raised to $19 from $9 at JMP Securities JMP Securities has increased confidence in Vanda's tasimelteon after reviewing data and receiving feedback from doctors. The firm keeps an Outperform rating on the stock. Sign up for a free trial to see the rest of the stories you've been missing.